Lupin has signed a licence and supply agreement with SteinCares to commercialise its biosimilar ranibizumab in Latin American ...

The global sales of ophthalmic lasers are estimated to be worth USD 976.8 million in 2024 and are anticipated to reach a value of USD 1,561.0 million by 2034. Sales are projected to rise at a CAGR of ...

According to the Ministry of Health and Welfare's National Health and Nutrition Survey, the prevalence of diabetes in 2023 ...

BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounja ...

Thai patients gain faster access to next-generation treatments as Zuellig and Lilly deepen their healthcare partnership.

Lupin partners with SteinCares to commercialize biosimilar ranibizumab in Latin America, enhancing retinal care access in the region.

Key trends include advanced multicolor laser adoption and increased outpatient treatments. Challenges include reimbursement issues and competition from alternative therapies. Leading players like ...

Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Aim Retinal oxygen metabolism is thought to be affected in diabetic retinopathy. The aim of this study was to test whether retinal vessel oxygen saturation is different in patients with diabetic ...

Fear is a natural response when something threatens your vision—but it’s also a signal to act quickly. Some retinal ...

Telangiectatic capillaries may have potential clinical relevance for diagnosis and treatment of diabetic macular edema.